Related Experiment Video
Updated: Apr 7, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
MicroRNAs in platelet function and cardiovascular disease
David D McManus1, Jane E Freedman1
1Cardiology Division, Department of Medicine, University of Massachusetts Medical School, AS7-1051, 368 Plantation Street, Worcester, MA 01605-4319, USA.
Insights
Platelets contain microRNAs (miRNAs) that regulate gene expression and influence cardiovascular health. Circulating platelet miRNAs show promise as biomarkers for cardiovascular disease risk and outcomes.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Hematology
Background:
- Cardiovascular diseases (CVD) are a major cause of death, with platelet function playing a critical role in thrombotic and atherogenic processes.
- Platelet activation is central to acute coronary syndromes and contributes to other conditions like stroke.
- Emerging research reveals that anucleate platelets contain transcripts, including microRNAs (miRNAs), involved in various cellular functions and intercellular communication.
Purpose of the Study:
- To explore the role of platelet-derived microRNAs (miRNAs) in cardiovascular disease pathogenesis and their potential as diagnostic or prognostic biomarkers.
- To investigate the mechanistic involvement of platelet miRNAs in hemostasis, thrombosis, and inflammatory processes within the vasculature.
Main Methods:
- Analysis of platelet transcripts, focusing on microRNAs (miRNAs) and their regulatory functions.
- Assessment of circulating levels of platelet miRNAs in relation to the presence and severity of cardiovascular diseases.
- Investigation into the functional roles of platelet-derived miRNAs in vascular homeostasis and disease.
Main Results:
- Platelet miRNAs are implicated in regulating gene expression, vascular homeostasis, inflammation, and platelet function.
- Circulating levels of platelet miRNAs correlate with the presence and extent of cardiovascular diseases, including atrial fibrillation and peripheral vascular disease.
- Platelet-derived miRNAs demonstrate mechanistic roles in hemostasis, thrombosis, and unstable coronary syndromes.
Conclusions:
- Platelet-derived microRNAs (miRNAs) are key players in cardiovascular pathophysiology, influencing hemostasis, thrombosis, and inflammation.
- Circulating platelet miRNAs represent promising biomarkers for assessing cardiovascular disease susceptibility, prognosis, and treatment response.
- Further research into platelet miRNAs could unlock novel therapeutic strategies for cardiovascular conditions.
Abstract:
Cardiovascular disease--a leading cause of morbidity and mortality among adults-is strongly influenced by platelet function through acute thrombotic and atherogenic mechanisms. Pathways that regulate platelet activity and lead to coronary occlusion are central to the pathogenesis of acute coronary syndromes. Platelet activation contributes to other thrombotic disorders and cardiovascular diseases, including stroke. Anucleate platelets are now understood to contain transcripts that might relate to other physiological or pathophysiological conditions, be released into the circulation, participate in protein formation, and engage in horizontal RNA transfer to other vascular cells. These platelet transcripts include microRNAs (miRNAs), which are small noncoding RNAs involved in many molecular processes, most notably regulation of gene expression. In platelets, these noncoding RNAs seem to participate in vascular homeostasis, inflammation, and platelet function. In addition, levels of platelet miRNAs in the circulation are associated with the presence or extent of cardiovascular diseases, such as atrial fibrillation and peripheral vascular disease. Accumulating data suggest mechanistic roles for platelet-derived miRNAs in haemostasis, thrombosis, and unstable coronary syndromes. In addition, evidence suggests that platelet-derived miRNAs might have important roles as biomarkers of cardiovascular disease susceptibility, prognosis, or treatment.
Related Concept Videos
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:38Inflammation
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:22MicroRNAs